Arrhythmogenic right ventricular dysplasia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 23 Jun 2026 04:03:33 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Arrhythmogenic right ventricular dysplasia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Spironolactone for Patients with Arrhythmogenic Right Ventricular Dysplasia (ARVD) https://clinicaltrials.eu/trial/study-on-spironolactone-for-patients-with-arrhythmogenic-right-ventricular-dysplasia-arvd/ Wed, 29 Apr 2026 14:23:25 +0000 https://clinicaltrials.eu/trial/study-on-spironolactone-for-patients-with-arrhythmogenic-right-ventricular-dysplasia-arvd/ This clinical trial is focused on studying a heart condition known as Arrhythmogenic Right Ventricular Dysplasia (ARVD). This condition affects the heart’s ability to pump blood effectively and can lead to irregular heartbeats. The study will use a medication called Spironolactone, which is taken in the form of tablets. Spironolactone is a type of medication that helps to block certain hormones that can affect the heart.

The purpose of the study is to evaluate how well Spironolactone can help reduce the worsening of the right side of the heart and decrease irregular heartbeats in patients with ARVD. Participants in the study will be randomly assigned to receive either Spironolactone or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for about one year, during which participants will have regular check-ups and tests to monitor their heart’s condition.

Throughout the study, participants will undergo tests such as echocardiography, which uses sound waves to create images of the heart, and a 24-hour Holter ECG, a device that records the heart’s electrical activity over a full day. These tests will help doctors see how the heart is functioning and if there are any changes in heart rhythm. The study aims to provide valuable information on the effectiveness of Spironolactone in managing ARVD and improving heart health.

]]> Study on the Effect of Atorvastatin in Slowing Down Arrhythmogenic Cardiomyopathy Progression in Patients with the Condition https://clinicaltrials.eu/trial/study-on-the-effect-of-atorvastatin-in-slowing-down-arrhythmogenic-cardiomyopathy-progression-in-patients-with-the-condition/ Wed, 29 Apr 2026 14:23:11 +0000 https://clinicaltrials.eu/trial/study-on-the-effect-of-atorvastatin-in-slowing-down-arrhythmogenic-cardiomyopathy-progression-in-patients-with-the-condition/ This clinical trial is focused on studying the effects of a medication called atorvastatin on a heart condition known as Arrhythmogenic Cardiomyopathy (ACM). ACM is a disease that affects the heart muscle, leading to irregular heartbeats and potentially causing heart failure. The trial aims to evaluate whether atorvastatin, a drug commonly used to lower cholesterol, can help reduce or delay the progression of this heart condition.

Participants in the study will be given atorvastatin in the form of film-coated tablets, which are taken orally. The study will also include a group of participants who will receive a placebo. The main goal is to see if atorvastatin can prevent the worsening of the heart’s right ventricle, which is a part of the heart that can be affected by ACM. The study will monitor various health indicators, including heart function and rhythm, using methods like echocardiograms (ECHO) and blood tests.

The trial will take place over a period of time, with regular check-ups to assess the participants’ heart health and any changes in their condition. The study is designed to provide valuable information on whether atorvastatin can be an effective treatment option for people with ACM, potentially improving their quality of life by managing the progression of the disease.

]]>